基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状

徐雅楠; 季楠; 赵志刚

doi:10.6039/j.issn.1001-0408.2023.19.10

您当前的位置：

首页 >

文章列表页 >

基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状

药学研究 | 更新时间：2023-10-09

- 基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状
- Visualization analysis of the therapy of recurrent high-grade gliomas based on CiteSpace
- 中国药房 2023年34卷第19期页码：2356-2364
- 作者机构：
  
  1.首都医科大学附属北京天坛医院药学部，北京　100070
  2.首都医科大学药学院，北京　100069
  3.首都医科大学附属北京天坛医院神经外科，北京　100070
- 作者简介：
  
  博士研究生。研究方向：临床药学、胶质瘤的治疗。E-mail：xuyanan1216@126.com
  主任药师，教授，博士生导师，博士。研究方向：临床药理、药事管理。E-mail：1022zzg@sina.com
- 基金信息：
  
  北京市卫生健康委员会首都卫生发展科研专项(首发2022-2-2047)
- DOI：10.6039/j.issn.1001-0408.2023.19.10
  中图分类号： R-1;R730.5;R979.1
- 纸质出版日期：2023-10-15，
  
  收稿日期：2023-03-15，
  
  修回日期：2023-08-07，
扫描看全文
徐雅楠,季楠,赵志刚.基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状 ^Δ[J].中国药房,2023,34(19):2356-2364.

XU Yanan,JI Nan,ZHAO Zhigang.Visualization analysis of the therapy of recurrent high-grade gliomas based on CiteSpace[J].ZHONGGUO YAOFANG,2023,34(19):2356-2364.
徐雅楠,季楠,赵志刚.基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状 ^Δ[J].中国药房,2023,34(19):2356-2364. DOI： 10.6039/j.issn.1001-0408.2023.19.10.

XU Yanan,JI Nan,ZHAO Zhigang.Visualization analysis of the therapy of recurrent high-grade gliomas based on CiteSpace[J].ZHONGGUO YAOFANG,2023,34(19):2356-2364. DOI： 10.6039/j.issn.1001-0408.2023.19.10.

摘要

目的

分析复发高级别胶质瘤的治疗领域热点、进展和前沿，为该领域研究提供参考。

方法

检索2005年1月1日－2022年3月14日Web of Science和中国知网数据库中的相关文献，使用CiteSpace 6.1.R3软件分别对纳入文献的国家、作者、机构、关键词等进行计量分析，生成可视化网络图谱和数据。

结果

共纳入1 019篇英文文献，308篇中文文献。国际发文量保持增长，国内发文量平稳。机构和作者之间合作较丰富。美国的中心性大（0.38），发文量最多（442篇），主要研究机构有加州大学洛杉矶分校、德州大学MD安德森癌症中心、丹娜-法伯癌症研究所等，重要的研究者有Wen、Cloughesy、Reardon等。国内研究团队相对固定、封闭。国际上，肿瘤发生机制和耐药机制是基础研究的重点，我国研究较少。放疗、化疗、靶向治疗、联合治疗是国际上研究较多的治疗方法，免疫治疗、光动力治疗是近几年新兴的疗法。我国对替莫唑胺和放疗研究较多。

结论

国际对治疗复发高级别胶质瘤的关注和投入在不断加大，美国在该领域具有极高影响力。目前放疗、传统化疗和贝伐珠单抗仍是复发高级别胶质瘤的主要治疗方式；免疫治疗、光动力治疗等新兴治疗方法有待更多尝试和研究。

Abstract

OBJECTIVE

To analyze the hotspots， progress and frontiers of the therapy of recurrent high-grade gliomas， and to provide a reference for the research in this field.

METHODS

The relevant literature were retrieved from the Web of Science and CNKI during Jan. 1st， 2005-Mar. 14th， 2022. CiteSpace 6.1.R3 software was used to quantitatively analyze the countries， authors， institutions and keywords of the included literature to form visual network maps and generate data.

RESULTS

A total of 1 019 English papers and 308 Chinese papers were included. The number of international publications kept growing and the number of domestic publications remained stable. Institutions and authors cooperated extensively. The United States featured a large centrality （0.38） and the largest number of publications （442）， with major research institutions such as the University of California San Francisco， University Texas MD Anderson Cancer Center， Dana-Farber Cancer Institute， and important researchers such as Wen， Cloughesy， Reardon， and so on. Domestic research groups were relatively fixed and closed. Internationally， the mechanism of tumorigenesis and drug resistance were the focus of basic research， while there was less basic research in China. Radiotherapy， chemotherapy， targeted therapy and combination therapy were studied the most internationally. Immunotherapy and photodynamic therapy were emerging therapies in recent years. In China， temozolomide and radiotherapy were the main research directions.

CONCLUSIONS

International attention and investment in the treatment of recurrent high-grade glioma are increasing. The United States has a high influence in this field. Currently， radiotherapy， traditional chemotherapeutic agents and bevacizumab are still the main treatment for recurrent high-grade glioma. Novel therapeutic approaches， including immunotherapy and photodynamic therapy， warrant more attempts and research.

关键词

高级别胶质瘤复发治疗CiteSpace可视化分析

Keywords

recurrencetherapyCiteSpacevisualization analysis

references

杨学军，陈宏，李佳博，等. 2021年世界卫生组织中枢神经系统肿瘤分类（第五版）整合及分层诊断解读[J]. 中国现代神经疾病杂志，2021，21（9）：764-768.

YANG X J，CHEN H，LI J B，et al. Integrated and layered diagnoses in the 2021 WHO classification of tumors of the central nervous system （fifth edition） [J]. Chin J Contemp Neurol Neurosurg，2021，21（9）：764-768.

NABORS L B，PORTNOW J，AHLUWALIA M，et al. Central nervous system cancers，version 3.2020，NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw，2020，18（11）：1537-1570.

STUPP R，BRADA M，VAN DEN BENT M J，et al. High-grade glioma：ESMO clinical practice guidelines for diagnosis，treatment and follow-up[J]. Ann Oncol，2014，25（Suppl 3）：iii93-iii101.

CHEN C M，HU Z G，LIU S B，et al. Emerging trends in regenerative medicine：a scientometric analysis in CiteSpace[J]. Expert Opin Biol Ther，2012，12（5）：593-608.

CHEN C M，SONG M. Visualizing a field of research：a methodology of systematic scientometric reviews[J]. PLoS One，2019，14（10）：e0223994.

STUPP R，WONG E T，KANNER A A，et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma：a randomised phase Ⅲ trial of a novel treatment modality[J]. Eur J Cancer，2012，48（14）：2192-2202.

杨一涵，程静，饶婷，等. 基于CiteSpace对治疗血管性痴呆的可视化分析[J]. 中国中药杂志，2022，47（22）：6235-6248.

YANG Y H，CHENG J，RAO T，et al. Visualization of research in treatment of vascular dementia by CiteSpace[J]. China J Chin Mater Med，2022，47（22）：6235-6248.

范婷，杨树，赵志刚. 基于CiteSpace的国内外抗菌药物透过血脑屏障的研究进展及可视化分析[J]. 中国抗生素杂志，2019，44（7）：868-875.

FAN T，YANG S，ZHAO Z G. Research of the penetration of antibiotics through the blood-brain barrier and visuali-zation analysis and abroad based on CiteSpace[J]. Chin J Antibiot，2019，44（7）：868-875.

DANG Q，LUO Z M，OUYANG C H，et al. First syste- matic review on health communication using the CiteSpace software in China：exploring its research hotspots and frontiers[J]. Int J Environ Res Public Health，2021，18（24）：13008.

WEN P Y，MACDONALD D R，REARDON D A，et al. Updated response assessment criteria for high-grade gliomas：response assessment in neuro-oncology working group[J]. J Clin Oncol，2010，28（11）：1963-1972.

REARDON D A，DESJARDINS A，PETERS K B，et al. Phase Ⅱ study of carboplatin，irinotecan，and bevacizumab for bevacizumab naïve，recurrent glioblastoma[J]. J Neurooncol，2012，107（1）：155-164.

VREDENBURGH J J，DESJARDINS A，2ndHERNDON J E，et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme[J]. J Clin Oncol，2007，25（30）：4722-4729.

FRIEDMAN H S，PRADOS M D，WEN P Y，et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma[J]. J Clin Oncol，2009，27（28）：4733-4740.

REARDON D A，DESJARDINS A，VREDENBURGH J J，et al. Rindopepimut with bevacizumab for patients with relapsed EGFRvⅢ-expressing glioblastoma （ReACT）：results of a double-blind randomized phase Ⅱ trial[J]. Clin Cancer Res，2020，26（7）：1586-1594.

LOMBARDI G，DE SALVO G L，BRANDES A A，et al. Regorafenib compared with lomustine in patients with relapsed glioblastoma （REGOMA）：a multicentre，open-label，randomised，controlled，phase 2 trial[J]. Lancet Oncol，2019，20（1）：110-119.

LE RHUN E，PREUSSER M，ROTH P，et al. Molecular targeted therapy of glioblastoma[J]. Cancer Treat Rev，2019，80：101896.

TUNCEL G，KALKAN R. Receptor tyrosine kinase-ras-PI3 kinase-Akt signaling network in glioblastoma multiforme[J]. Med Oncol，2018，35（9）：122.

AGARWAL S，SURI V，SHARMA M C，et al. Therapy and progression-induced O6-methylguanine-DNA methyltransferase and mismatch repair alterations in recurrent glioblastoma multiforme[J]. Indian J Cancer，2015，52（4）：568-573.

LAWRIE T A，GILLESPIE D，DOWSWELL T，et al. Long-term neurocognitive and other side effects of radiotherapy，with or without chemotherapy，for glioma[J]. Cochrane Database Syst Rev，2019，8（8）：CD013047.

OLDRINI B，VAQUERO-SIGUERO N，MU Q H，et al. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas[J]. Nat Commun，2020，11（1）：3883.

CHANG S S，ZHANG P X，CAIRNCROSS J G，et al. Phase Ⅲ randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anapla- stic astrocytoma：results of NRG Oncology RTOG 9813[J]. Neuro Oncol，2017，19（2）：252-258.

TAAL W，OOSTERKAMP H M，WALENKAMP A M，et al. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma （BELOB trial）：a randomised controlled phase 2 trial[J]. Lancet Oncol，2014，15（9）：943-953.

WICK W，GORLIA T，BENDSZUS M，et al. Lomustine and bevacizumab in progressive glioblastoma[J]. N Engl J Med，2017，377（20）：1954-1963.

KLEIJN A，VAN DEN BOSSCHE W，HAEFNER E，et al. It-16 combination treatment with delta24-RGD and temozolomide improves survival and affects intratumoral immune cell subsets in a murine malignant glioma model[J]. Neuro Oncol，2014，16（suppl_5）：v112-v113.

BRYANT J，BROWN M，GROMEIER M. Chemotherapy enhances oncolytic recombinant poliovirus efficacy[J]. J Immunother Cancer，2017，5（Suppl2）.

KHASRAW M，AMERATUNGA M，LASSMAN A B， et al. A meta-analysis of antiangiogenic therapy for gliobla- stoma（GBM）[J]. J Clin Oncol，2014，32（15_suppl）：2047.

AMERATUNGA M，PAVLAKIS N，WHEELER H，et al. Anti-angiogenic therapy for high-grade glioma[J]. Cochrane Database Syst Rev，2018，11（11）：CD008218.

WELLER M，VAN DEN BENT M，PREUSSER M，et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood[J]. Nat Rev Clin Oncol，2021，18（3）：170-186.

国家卫生健康委员会医政医管局，中国抗癌协会脑胶质瘤专业委员会，中国医师协会脑胶质瘤专业委员会. 脑胶质瘤诊疗指南：2022版[J]. 中华神经外科杂志，2022，38（8）：757-777.

Medical Administration Bureau of National Health Commission of the People’s Republic of China，Brain Glioma Professional Committee of China Anti-Cancer Association，China Medical Doctor Association Brain Glioma Professional Committee of Chinese Medical Doctor Association. Diagnosis and treatment guidelines for brain glioma：2022 edition[J]. Chin J Neurosur，2022，38（8）：757-777.

PUDUVALLI V K，WU J，YUAN Y，et al. A Bayesian adaptive randomized phase Ⅱ multicenter trial of bevacizumab with or without vorinostat in adults with recurrent glioblastoma[J]. Neuro Oncol，2020，22（10）：1505-1515.

SCHIFF D，JAECKLE K A，ANDERSON S K，et al. Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma：North Central Cancer Treatment Group Study/Alliance N0572[J]. Cancer，2018，124（7）：1455-1463.

VAN DEN BENT M，EOLI M，SEPULVEDA J M，et al. INTELLANCE 2/EORTC 1410 randomized phase Ⅱ study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma[J]. Neuro Oncol，2020，22（5）：684-693.

WEN P Y，TOUAT M，ALEXANDER B M，et al. Bupar- lisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation：an open-label，multicenter，multi-arm，phase Ⅱ trial[J]. J Clin Oncol，2019，37（9）：741-750.

DUERINCK J，FOUR S D，BOUTTENS F，et al. Rando- mized phase Ⅱ trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma[J]. J Neurooncol，2018，136（1）：115-125.

NORDEN A D，SCHIFF D，AHLUWALIA M S，et al. Phase Ⅱ trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas[J]. J Neurooncol，2015，121（2）：297-302.

FROSINA G. Radiotherapy of high-grade gliomas：first half of 2021 update with special reference to radiosensitization studies[J]. Int J Mol Sci，2021，22（16）：8942.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析

国内外中药酒制相关研究的可视化分析

2013－2023年中医药治疗溃疡性结肠炎的文献计量学分析

人工智能应用于医院药学服务领域的文献计量学分析

酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析